 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Exelixis, Inc.
 |
Exelixis, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Exelixis files for upto $150 mln stock offering Jul 27 2001 03:52 PM PDT
Morningstar Japan half-year profits up 54 pct y/y Jul 18 2001 01:39 AM PDT
Bristol-Myers, Exelixis collaborate on new cancer drug Jul 18 2001 01:38 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
We've come a long way, baby, but we still have a lot in common with the fruit fly. Exelixis (Greek for "evolution") uses model organisms, such as fruit flies and roundworms, to gather and compare genetic data to speed the development of drugs, insecticides, and animal health products. Minority-owned affiliate Artemis Pharmaceuticals, a German biotech the firm plans to buy, performs similar testing on mice and zebra fish. Exelixis has an agricultural biotech joint venture, GenOptera, with Bayer (which accounts for more than half of its revenues) and collaborative deals with such companies as Pharmacia (almost 40% of revenues) and Bristol-Myers Squibb. Its Exelixis Plant Sciences unit focuses on plant genomics.
COMPETITION |
 |
Celera Genomics Group (CRA)
Lexicon Genetics Incorporated (LEXG)
Paradigm Genetics, Inc. (PDGM)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 24.80
1-Yr. Sales Growth: 136.2%
Employees: 357
Revenue per employee: $69,467.79
KEY PEOPLE |
 |
George A. Scangos
CEO
Glen Y. Sato
CFO
CONTACT INFO |
 |
170 Harbor Way
South San Francisco, CA 94080
US
Phone: 650-837-7000
Fax: 650-837-7226
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |